Microsoft word - wanbury press release


Wanbury enters Urinary infection antibiotic market with NDDS Nitrofur SR

October 13, Mumbai:
Wanbury Ltd, one of the fastest growing pharma
companies in the domestic market, has launched its New Drug Delivery System (NDDS) product Nitrofur SR (Nitrofurantoin-100mg, sustained release) targeted at Urinary Tract Infections (UTI), for the first time in India. The molecule Nitrofurantoin, is highly effective in the treatment of urinary tract infection. However, since the available brands are of the instant release (IR) category and have to be taken by the patient four times a day, users suffer from side-effects like gastro-intestinal irritation and burning sensation, leading to poor “Wanbury’s Nitrofur SR, due to its unique Hydrophilic Polymer Matrix or HPM (NDDS) technology, makes it a once-a-day, sustained release product. It is highly effective, compared to instant release formulations and is without any side-effects,” said Dr. Rajaram Samant, Director - Marketing & Sales, Wanbury. Nitrofur SR is also proved to be safe, when taken during pregnancy and has been endorsed by authorities like World Health Organisation (WHO), US FDA, American Col ege of Obstetricians and Gynaecologists (ACOG), he said. Wanbury is the third company in India to have entered the unexplored market of Nitrofurantoin. According to industry estimates, the size of the UTI market in India is about Rs. 1200 cr, annual y growing at 14%. It’s alarming that in India, over 28% of the women visiting gynaecologists suffer from UTI. “We wil be targeting this 28 % population. We plan Nitrofur SR sales of Rs. 10cr in the first year of the launch and hope to capture a substantial share of the UTI market in the next three years,” said Dr. Samant. Wanbury wil be marketing the product with leading gynaecologists and Wanbury is acknowledged for its strong Gynaec portfolio with brands like Cpink and Folinine. Gynaecologists treating UTI are currently not satisfied with available UTI antibiotics in the market. This provides an edge for Wanbury to carve a niche in the market as Nitrofur SR adds strong value to existing array of products. Wanbury ranks 52nd as per ORG-IMS and is growing at 87%. Wanbury has successful track record of brand launches as its products are need based with unique advantage catering to needs of the patients. In view of the above fact 4 of the Company’s products viz. Cpink, Rabiplus, Folinine and Adtrol are in the ‘Top 3’ brands in respective segments. At Wanbury, its corporate philosophy to support social causes is fol owed to the word. Recently, the Company supported a noble cause – National Eclampsia Registry project initiated by Federation of Obstetric and Gynaecological Societies of India (FOGSI) & the Indian Col ege of Obstetricians & Gynaecologists (ICOG). Eclampsia is hypertension during pregnancy, which leads to convulsions and may lead to the death of the mother as wel as the child. Wanbury has provided the platform to more than 20,000 gynaec doctors al over India to discuss issues related to Eclampsia.

Media contacts

Adfactors PR
Prabodh Menon Mobile – 9820920527

Nitin Malekar - 9892755568



Sleep_19-20-V3N5 10/17/08 6:19 PM Page 19Sleep Diagnosis and Therapy 2008; V3 N5, P19-20 K. Hansen Care of Patients at Risk for Sleep Apnea Who Receive Sedation Sleep apnea is the most widely known sleep disorder besidespatient for the effects of sedation, it is critical to differentiateinsomnia. Estimates are that more than 18 million people havebetween sedation and sleepiness: does the pa

BAY AREA LUPUS FOUNDATION plans recognize how valuable the benefit isand are working very hard to maintain an NEW LAWS NEXT YEAR TO PROTECT CONSUMERS don’t examine whether the health plan paysto obtain medications and insurers trying to Published September 29, 1998, keep a lid on costs has led to numerous con- Los Angeles Times sumer complaints, and resulted in new laws Dr

Copyright © 2010 Find Medical Article